Teva Pharmaceutical Industries (TEVA) to Release Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is scheduled to release its earnings data before the market opens on Wednesday, November 6th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.62 per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. On average, analysts expect Teva Pharmaceutical Industries to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $18.43 on Wednesday. The stock has a market capitalization of $20.87 billion, a price-to-earnings ratio of -44.95, a PEG ratio of 1.29 and a beta of 0.88. Teva Pharmaceutical Industries has a 52-week low of $8.23 and a 52-week high of $19.08. The stock’s 50 day moving average price is $18.01 and its two-hundred day moving average price is $16.83. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. UBS Group increased their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Barclays increased their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $19.67.

Insider Activity

In other news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now directly owns 45,060 shares of the company’s stock, valued at $777,285. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.